Policymakers increasingly are focused on identifying policy mechanisms to reduce the numbers of infections that may result from patients’ stays in hospitals and other health care facilities. Infectious diseases physicians work in collaboration with other health care personnel (HCP) to develop and implement evidence-based practices to prevent and control these health care-associated infections (HAIs). Policy decisions which support evidence-based practices are the best approach for preventing HAIs and protecting patients, HCP, and communities.
Contact your Congressional representative through our Advocacy Center to show your support for policy decisions supported by evidence-based practices to prevent health care-associated infections, protect patients, health care personnel and and communities.Take Action!
IDSA and SHEA Submit Joint Comments to Federal Health Safety Agency on Respiratory Protective Devices (PDF)
IDSA and SHEA submitted comments to the US National Institute for Occupational Safety and Health (NIOSH) on respiratory protective devices (RPDs) used in health care.
IDSA Comments to USPSTF Draft Recommendation Statement on Screening for HBV Infection (PDF)
IDSA supports the US Preventive Services Task Force (USPSTF) grade "B" recommendation to screen for Hepatitis B Virus (HBV) in adults at high risk for infection.
IDSA Comments on Pulmonary Tuberculosis: Developing Drugs for Treatment (PDF)
IDSA submitted comments to FDA's draft guidance for industry entitled "Pulmonary Tuberculosis: Developing Drugs for Treatment." IDSA applauded FDA's draft guidance as a major step forward for the clinical development of improved tuberculosis treatment regimens and providing much-needed clarity for sponsors interested in TB product development.
IDSA Leads Letter to HHS Secretary on AMR (PDF)
IDSA led a group of over forty organizations representing health care providers, patients, public health, and industry to thank HHS Secretary Tom Price for his upcoming participation in the World Health Assembly, and to continue domestic and international work to advance a robust response to antimicrobial resistance (AMR) that reflects the US commitment to infection prevention, antimicrobial stewardship, surveillance, and innovation.
IDSA Letter to FDA on Drug Shortages (PDF)
IDSA sent a letter to FDA in response to an Emerging Infections Network survey of ID physicians that showed continued shortages of vital anti-infective drugs despite actions taken by FDA and Congress in 2012. IDSA collaborated with stakeholders to determine what additional information is needed to fully assess the issues leading to these shortages and what solutions may help to address underlying problems.